Ascentage Pharma Group International (AAPG)vsAbbVie Inc (ABBV)
AAPG
Ascentage Pharma Group International
$18.99
+11.09%
HEALTHCARE · Cap: $1.63B
ABBV
AbbVie Inc
$246.04
+0.89%
HEALTHCARE · Cap: $430.82B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 11115% more annual revenue ($64.39B vs $574.12M). ABBV leads profitability with a 9.8% profit margin vs -216.5%. ABBV earns a higher WallStSmart Score of 73/100 (B).
AAPG
Avoid27
out of 100
Grade: F
ABBV
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AAPG.
Margin of Safety
-63.1%
Fair Value
$150.90
Current Price
$246.04
$95.14 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 117.0% year-over-year
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Areas to Watch
Trading at 9.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AAPG
The strongest argument for AAPG centers on Revenue Growth. Revenue growth of 117.0% demonstrates continued momentum.
Bull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bear Case : AAPG
The primary concerns for AAPG are Price/Book, EPS Growth, Market Cap.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Key Dynamics to Monitor
AAPG profiles as a hypergrowth stock while ABBV is a value play — different risk/reward profiles.
AAPG carries more volatility with a beta of 0.66 — expect wider price swings.
AAPG is growing revenue faster at 117.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 27/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascentage Pharma Group International
HEALTHCARE · BIOTECHNOLOGY · USA
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?